Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

Syntara

Status and phase

Completed

Phase 3

Conditions

Asthma

Treatments

Procedure: Exercise challenge

Drug: Methacholine

Drug: Aridol

Study type

Interventional

Funder types

Industry

Identifiers

NCT00252291

DPM-A-305

Details and patient eligibility

About

This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 >70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.

Sex

All

Ages

6 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have given informed consent to participate in this study in accordance with local regulations prior to any procedures being performed
Have signs and symptoms suggestive of asthma according to the NIH Questionnaire but has not been given a firm diagnosis of asthma or a firm exclusion of the diagnosis of asthma (e.g. has an equivocal diagnosis of asthma or been referred for further investigation of asthma type symptoms)
Have at least Step 1 symptoms according to the NAEPPII asthma severity grading
Have an FEV1 ≥ 70% of the predicted value at Screening Visit (Visit 1) baseline
Be between 6 and 50 years
Be able to perform all of the techniques necessary to measure lung function including an exercise challenge, Aridol challenge and methacholine challenge
Be able to understand the requirements of the study and be able to complete all of the forms necessary including the NIH Questionnaire
Be taking effective birth control if female of childbearing potential

Exclusion criteria

Use medications six weeks prior to the Screening Visit (Visit 1) or during the study that would interfere with bronchial provocation challenge testing (see Table 1, section 3.3.3.4)
Currently use cholinesterase-inhibitor medication (for myasthenia gravis)
Have had upper or lower respiratory tract infection within the previous 4 weeks
Have known aortic or cerebral aneurysm, cirrhosis or portal hypertension
Have had recent major surgery
Have had recent cataract surgery
Have a history of heart disease that would increase risk of performing exercise, methacholine or Aridol challenge
Have had cardiac ischemia or malignant arrhythmias
Have uncontrolled hypertension (systolic blood pressure ≥ 180 and diastolic blood pressure ≥ 100)
Have orthopedic limitations
Have smoked within the past year (average > 1 cigarette per week), or have a ≥ 10 pack year smoking history
Have other chronic restrictive or obstructive pulmonary diseases (cystic fibrosis, COPD, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension, hypercapnia)
Be skin test positive to seasonal and perennial aeroallergens that are present in the environment during the time that the subject is enrolled in the study, or if skin test positive to these aeroallergens the subject must not report worsening of symptoms when exposed to these aeroallergens during the time that the subject is participating in the study
Have a medical condition that in the opinion of the Investigator would impair the ability of the subject to participate
Have an inability to perform spirometry of acceptable quality
Be intolerant to Aridol, methacholine or albuterol
Be pregnant or lactating
Have participated in any other investigative drug study parallel to, or within 4 weeks of study entry
Be an Investigator, site employee or otherwise be directly affiliated with the study site including being a member of the immediate family of an Investigator, site employee (where an immediate family member is defined as spouse, parent, child or sibling, whether biological or legally adopted or in foster care)
Have a body mass index (BMI) ≥ 30
Have been diagnosed at Screening Visit (Visit 1) as definitively having or not having asthma; patients that will not continue in the study include those given the following diagnosis: asthma is extremely likely or definite (95 to 100% likelihood) or asthma is very unlikely or excluded (0 to < 5% likelihood)
Have previously been enrolled in this study at this or at any other clinical trials site
Have previously received an Aridol challenge
Have a clinically significantly abnormal chest x-ray